We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
+9.18%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$1.17B
AUM Growth
-$203M
Cap. Flow
-$271M
Cap. Flow %
-23.1%
Top 10 Hldgs %
53.52%
Holding
83
New
18
Increased
13
Reduced
24
Closed
26

Top Buys

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$20M
2
NTRA icon
Natera
NTRA
+$15.8M
3
COR icon
Cencora
COR
+$15.4M
4
MASI
Masimo
MASI
+$15.1M
5
ARQT icon
Arcutis Biotherapeutics
ARQT
+$12.9M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$61.6M
2
ABBV icon
AbbVie
ABBV
+$54.1M
3
ELV icon
Elevance Health
ELV
+$38.4M
4
ARGX icon
argenx
ARGX
+$35.8M
5
UHS icon
Universal Health Services
UHS
+$29.2M

Sector Composition

Rank Sector Weight
1 Healthcare 94.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBIX icon
51
Neurocrine Biosciences
NBIX
$16.8B
$1.61M 0.14%
+12,821
New +$1.47M
ERAS icon
52
Erasca
ERAS
$6.3B
$1.36M 0.12%
1,072,224
-2,417,335
-69% -$3.24M
GPCR icon
53
Structure Therapeutics
GPCR
$3.41B
$1.17M 0.1%
56,594
+16,194
+40% +$356K
VKTX icon
54
Viking Therapeutics
VKTX
$3.7B
$1,000K 0.09%
+37,729
New +$993K
SGMT icon
55
Sagimet Biosciences
SGMT
$439M
$686K 0.06%
90,000
-559,006
-86% -$2.36M
HOWL icon
56
Werewolf Therapeutics
HOWL
$17.2M
$437K 0.04%
401,110
-2,105,410
-84% -$2.17M
ACLX
57
DELISTED
Arcellx
ACLX
– –
-15,488
Closed -$1.02M
AZN icon
58
AstraZeneca
AZN
$263B
– –
-75,100
Closed -$11M
BDX icon
59
Becton Dickinson
BDX
$45.6B
– –
-91,571
Closed -$21M
BHVN icon
60
Biohaven
BHVN
$2.03B
– –
-197,307
Closed -$4.74M
CAPR icon
61
Capricor Therapeutics
CAPR
$223M
– –
-140,681
Closed -$1.34M
CELC icon
62
Celcuity
CELC
$4.21B
– –
-53,349
Closed -$539K
CNC icon
63
Centene
CNC
$30.7B
– –
-135,398
Closed -$8.22M
ELV icon
64
Elevance Health
ELV
$81.5B
– –
-88,222
Closed -$38.4M
IOVA icon
65
Iovance Biotherapeutics
IOVA
$1.82B
– –
-132,152
Closed -$440K
IQV icon
66
IQVIA
IQV
$38.7B
– –
-111,854
Closed -$19.7M
KROS icon
67
Keros Therapeutics
KROS
$199M
– –
-104,323
Closed -$1.06M
PMVP icon
68
PMV Pharmaceuticals
PMVP
$59.2M
– –
-3,301,942
Closed -$3.6M
SNDX icon
69
Syndax Pharmaceuticals
SNDX
$1.69B
– –
-926,424
Closed -$11.4M
SRPT icon
70
Sarepta Therapeutics
SRPT
$1.57B
– –
-50,809
Closed -$3.24M
SWTX
71
DELISTED
SpringWorks Therapeutics
SWTX
– –
-26,437
Closed -$1.17M
TMO icon
72
Thermo Fisher Scientific
TMO
$213B
– –
-21,897
Closed -$10.9M
TSBX
73
DELISTED
Turnstone Biologics
TSBX
– –
-932,348
Closed -$382K
UHS icon
74
Universal Health Services
UHS
$10.2B
– –
-155,520
Closed -$29.2M
VERV
75
DELISTED
Verve Therapeutics
VERV
– –
-155,495
Closed -$711K
1 2
3
4

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
CF
Corebridge Financial Houston, Texas $1.09B AUM 1.85% 1-Year Est. Return
MIA
MMBG Investment Advisors Miami, Florida $1.09B AUM 30.96% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return

PFM Health Sciences's Q2 2025 Portfolio in Review

As of Q2 2025, PFM Health Sciences held 83 positions worth $1.17B, down 15% from $1.38B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

PFM Health Sciences withdrew a net $271M in Q2 2025, closing 26 positions and reducing 24 holdings. Its most notable exit was Vertex Pharmaceuticals, an estimated $61.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 92% a quarter earlier.

Against the trend, PFM Health Sciences opened a new position in Teva Pharmaceuticals worth $20.8M.

  • PFM Health Sciences's largest Q2 2025 buy was Teva Pharmaceuticals: 1,238,846 shares worth $20.8M.
  • PFM Health Sciences added most to Humana in Q2 2025, an estimated $11.5M increase.
  • PFM Health Sciences's biggest Q2 2025 reduction was AbbVie, cutting an estimated $54.1M.
  • PFM Health Sciences fully exited Vertex Pharmaceuticals in Q2 2025, selling an estimated $61.6M.
  • PFM Health Sciences's ten largest holdings make up 54% of its $1.17B portfolio in Q2 2025.
  • PFM Health Sciences opened 18 new positions and closed 26 in Q2 2025.
  • PFM Health Sciences's portfolio value fell 15% quarter-over-quarter to $1.17B.

Based on PFM Health Sciences's 13F filing for Q2 2025, filed 14 Aug 2025.